Meibomian gland dysfunction (MGD) is a complex, multifactorial disorder that can lead to altered tear film composition and ocular surface disease. In fact, MGD is one of the most common causes of dry eye disease (DED). Although multiple treatment options are available, therapies that target the underlying pathophysiology of the disease are lacking. Emerging agents with novel mechanisms for treating MGD may ultimately provide new treatment alternatives.

This podcast episode provides a review of some of the key highlights from a live symposium held during the American Academy of Optometry Annual Meeting 2022 in October.

Faculty

Kelly K. Nichols, OD, MPH, PhD, FAAO
Dean
University of Alabama at Birmingham School of Optometry
Birmingham, AL

Marc R. Bloomenstein, OD, FAAO
Director, Optometric Services
Schwartz Laser Eye Center
Scottsdale, AZ